Group 1 - The company Shanghai Pharmaceutical Group Co., Ltd. has received approval from the National Medical Products Administration for its injectable Cefazolin Sodium, indicating that the drug has passed the consistency evaluation for quality and efficacy of generic drugs [1][2] - The injectable Cefazolin Sodium is indicated for the treatment of infections caused by sensitive bacteria, including respiratory, urinary, skin, soft tissue, bone, joint infections, sepsis, infective endocarditis, hepatobiliary infections, reproductive system infections, and for perioperative infection prevention [3] - The company has invested approximately RMB 3.3241 million in the research and development of this drug's consistency evaluation as of the date of the announcement [3] Group 2 - According to the IQVIA database, the procurement amount for injectable Cefazolin Sodium in hospitals in mainland China is projected to be RMB 1,107.58 million in 2025 [4] - The approval of the drug through the consistency evaluation is expected to enhance its market share and competitiveness, while also providing valuable experience for the company in conducting future consistency evaluations for other products [5]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shenyang Pharmaceutical Co., Ltd. (referred to as "Shenyang Pharmaceutical"), has received the "Drug Supplement Application Approval Notice" from the National Medical Products Administration for its injectable Cefazolin Sodium, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The injectable Cefazolin Sodium is indicated for the treatment of infections caused by sensitive bacteria, including respiratory infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, sepsis, infective endocarditis, liver and biliary system infections, reproductive system infections, and for the prevention of infections during surgery [1]

Group 1 - The core point of the article is that Anglikon (002940.SZ) has received approval from the National Medical Products Administration for the drug Domperidone tablets, which has passed the consistency evaluation of quality and efficacy for generic drugs [2] - The drug is indicated for conditions such as dyspepsia, abdominal distension, belching, nausea, vomiting, and abdominal pain [2] - Passing the consistency evaluation is expected to enhance the company's market competitiveness, although sales may be influenced by policy and market environment factors, leading to uncertainty [2]

Core Viewpoint - Hainan Huluwa Pharmaceutical Group Co., Ltd. has received the drug registration certificate for inhaled ipratropium bromide solution from the National Medical Products Administration, which is expected to enhance the company's product line and positively impact its development [1][4]. Drug Information - The drug is named inhaled ipratropium bromide solution, classified as a Class 4 chemical drug, with specifications of 2ml:0.25mg and 2ml:0.5mg [1][2]. - The 2ml:0.25mg formulation is indicated for the treatment of reversible airway obstruction caused by acute or chronic asthma when used in conjunction with inhaled β-agonists [2]. - The 2ml:0.5mg formulation serves as a bronchodilator for the maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and can also be used with inhaled β-agonists for acute bronchospasm [2]. - The original manufacturer of the drug is Boehringer Ingelheim Pharma GmbH & Co. KG, which first received approval in the UK in 1986 and was launched in China in 2004 [2]. R&D Investment - The company has invested a total of RMB 5.9089 million in the research and development of this product to date (unaudited) [3]. Market Context - As of the date of this announcement, there are 29 other domestic companies that have received approval to market inhaled ipratropium bromide solution [2].

Core Viewpoint - The announcement highlights that Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.'s subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., has received approval for its injectable penicillin sodium product, which is expected to enhance its market competitiveness [1] Group 1 - The product, injectable penicillin sodium 0.96g (1.6 million units), has passed the consistency evaluation for generic drug quality and efficacy [1] - The research and development expenses incurred by Tianxin Pharmaceutical for this product amount to approximately RMB 2.5926 million (unaudited) [1] - The approval is seen as a positive development for the company's product portfolio, potentially increasing its market share [1]

Core Viewpoint - Recently, Harbin Pharmaceutical Group Co., Ltd. (stock code: 600664) announced that its subsidiary, Harbin Pharmaceutical Group Pharmaceutical Factory, received a "Drug Supplement Application Approval Notice" from the National Medical Products Administration for injectable Cefotaxime Sodium, which has passed the consistency evaluation of generic drug quality and efficacy [1] Group 1 - The drug is indicated for infections caused by sensitive bacteria, including lower respiratory tract infections, urogenital infections, and gynecological infections [1] - As of the announcement date, there are a total of 239 production approvals for injectable Cefotaxime Sodium in China, with 37 manufacturers having passed the consistency evaluation [1] - The domestic sales revenue for the drug is projected to be 1.55 billion yuan in 2024, with 889 million yuan expected in the first three quarters of 2025 [1] Group 2 - The company has invested approximately 8.1573 million yuan in research and development for the consistency evaluation project of this drug [1]

Core Viewpoint - North China Pharmaceutical Co., Ltd. has announced that its wholly-owned subsidiary, Hebei Huamin Pharmaceutical Co., Ltd., has received the Drug Registration Certificate for Cefprozil Tablets (0.25g) from the National Medical Products Administration, which is expected to enhance the company's product portfolio and market competitiveness [1][6]. Group 1: Drug Registration Details - The Drug Registration Certificate for Cefprozil Tablets (0.25g) was approved by the National Medical Products Administration [1]. - Cefprozil is a second-generation cephalosporin antibiotic, initially developed by Bristol-Myers Squibb in 1991, and was the first oral cephalosporin approved by the FDA for treating pediatric otitis media and sinusitis [1][2]. Group 2: Indications and Market Situation - The approved indications for Cefprozil in China include treatment for upper respiratory infections, lower respiratory infections, and skin and soft tissue infections caused by sensitive bacteria [2]. - Currently, there are 10 companies, including Huamin, that hold the Drug Registration Certificate for Cefprozil Tablets (0.25g) in China. Sales figures for Cefprozil Tablets in sample hospitals from 2023 to the first three quarters of 2025 are reported as 141.7 million, 134.99 million, and 74.22 million yuan respectively [5]. Group 3: Research and Development Investment - The cumulative R&D investment for the drug has reached 14.6458 million yuan (unaudited) [3]. Group 4: Future Prospects - Following the receipt of the Drug Registration Certificate, the company can arrange for production and market the product [4].

Core Viewpoint - Beijing Zhongguancun Science and Technology Development (Holding) Co., Ltd. announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., has successfully passed the consistency evaluation for the generic drug Tramadol Hydrochloride Tablets (50mg) [1][2]. Group 1: Drug Approval Details - The drug name is Tramadol Hydrochloride Tablets, in tablet form, with a specification of 50mg [1]. - The approval notice number is 2026B00624, and the drug is classified as a chemical drug [1]. - The approval includes changes to the prescription, manufacturing process, production batch, quality standards, and shelf life [1]. Group 2: Market Context - The original drug has not been marketed in China, but there are currently eight generic versions approved, with three having passed the consistency evaluation [2]. - Beijing Huasu is the third domestic company to receive approval for this drug's consistency evaluation [2]. Group 3: Financial Investment - The total research and development investment for the consistency evaluation project of Tramadol Hydrochloride Tablets has reached approximately 5.9 million yuan [3]. Group 4: Impact on Company Performance - The approval is expected to enhance the market competitiveness of the drug and positively impact the company's operating performance [5]. - The company emphasizes the importance of drug research and development, maintaining strict quality control throughout the drug development, manufacturing, and sales processes [5].

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Tacrolimus capsules (0.5mg, 1mg), which are potent immunosuppressants used to prevent organ rejection after liver or kidney transplants [1] Group 1 - The Tacrolimus capsules were originally submitted for registration by Jiangsu Hechen Pharmaceutical Co., Ltd. in June 2024 and received a drug registration acceptance number [1] - During the review period, there was a change in the drug registration applicant, with the company becoming the marketing authorization holder [1] - The drug was approved on January 2026, and it is considered to have passed the consistency evaluation of quality and efficacy for generic drugs [1]

Core Viewpoint - The company has received approval for the production of Loxoprofen Sodium Gel Patch, which is expected to enhance its product line in orthopedic medications and improve its competitive position in the market [1][3]. Group 1: Drug Registration and Details - The company's subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., has obtained the Drug Registration Certificate for Loxoprofen Sodium Gel Patch from the National Medical Products Administration [1]. - Loxoprofen Sodium Gel Patch is indicated for the treatment of osteoarthritis, muscle pain, and swelling pain after injuries, with significant anti-inflammatory and analgesic effects [1]. - The total investment in this drug project, including research and development, has reached 7.0366 million yuan (approximately 1.01 million USD) as of the announcement date [1]. Group 2: Market Situation of Similar Drugs - A total of 15 companies in China have obtained drug registration certificates for Loxoprofen Sodium Gel Patch, including listed companies such as Jiutian Pharmaceutical, Darentang, and China Resources Sanjiu [2]. - According to Moen Pharmaceutical data, the total sales of Loxoprofen Sodium Gel Patch in hospitals for the first three quarters of 2025 reached 1.349 billion yuan (approximately 190 million USD), with retail sales in physical pharmacies amounting to 142 million yuan (approximately 20 million USD) in the first half of 2025 [2]. - Projected sales for 2024 are expected to be 1.709 billion yuan (approximately 240 million USD) in hospitals and 280 million yuan (approximately 40 million USD) in retail pharmacies [2]. Group 3: Impact on the Company - The approval of Loxoprofen Sodium Gel Patch will enrich the company's product line for orthopedic diseases, which already includes products like Xuanqi Jianguo Tablets and Tenghuang Jianguo Tablets [3]. - This new product is anticipated to enhance the company's competitiveness in the orthopedic medication market and improve overall profitability [3]. - The company emphasizes the importance of drug research and development while maintaining strict quality control in the manufacturing and sales processes [3].